首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷分子呈像/呈影劑

Gadoquatrane市場規模、佔有率和成長分析（按應用程式、最終用戶和地區分類）—2026-2033年產業預測

市場調查報告書

商品編碼

1907437

Gadoquatrane市場規模、佔有率和成長分析（按應用程式、最終用戶和地區分類）—2026-2033年產業預測

Gadoquatrane Market Size, Share, and Growth Analysis, By Application (Screening, Diagnosis), By End User (Hospital, Diagnostic Centres), By Region - Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，Gadoquatrane市場規模將達到 20 億美元，到 2025 年將達到 21 億美元，到 2033 年將達到 31.3 億美元，在預測期（2026-2033 年）內複合年成長率為 5.1%。

市場趨勢表明，磁振造影（MRI）造影劑市場正呈現顯著成長態勢，這主要得益於新型高效能大環钆基造影劑（mGBCA）—钆喹啉（Gadoquatrane）的問世。Gadoquatrane具有卓越的理化性質，包括高弛豫率、穩定性和極低的蛋白質結合率，同時其藥物動力學特徵與現有mGBCA相似，表現為快速的細胞外分佈和有效的腎臟排泄。這種不斷成長的需求主要源於癌症、神經系統疾病和心血管疾病等慢性疾病發生率的上升。先進的影像技術對於這些疾病的精準診斷和治療方案製定至關重要。此外，人口老化以及人們對非侵入性診斷方法的日益青睞預計也將顯著推動MRI造影劑市場的發展。

Gadoquatrane市場促進因素

Gadoquatrane市場主要受磁振造影（MRI）造影劑強勁需求的推動，而這又受到慢性病發病率上升、人口老化以及人們日益傾向於非侵入性診斷方法等因素的影響。此外，技術進步和醫療費用支出的成長也促進了這一成長趨勢。钆基造影劑（GBCA）因其在造影增強磁振造影（CE-MRI）中的有效性而備受認可，並已在全球數百萬例檢查中使用。 CE-MRI卓越的影像能力涵蓋多個醫學領域，有助於改善診斷和疾病管理，這使得Gadoquatrane成為未來臨床應用領域極具潛力的候選藥物。

Gadoquatrane市場的限制因素

多種因素限制了造影造影（MRI）造影劑的需求，並導致其價格下降。這些造影劑的高成本以及新出現的安全性問題是造成此趨勢的關鍵因素。此外，替代診斷方法的興起以及以價值為導向的醫療模式的轉變進一步加劇了這些限制。非造影MRI技術的進步提高了準確性和效率，從而減少了對造影劑的需求。隨著醫療成本的不斷上漲，患者和醫療服務提供者可能會更傾向於選擇更具成本效益的非造影方案。雖然造影劑通常被認為是安全的，但對潛在副作用的擔憂可能會導致一些人完全避免造影顯影劑，這可能會影響市場需求。

Gadoquatrane市場趨勢

由於钆基造影劑相關的健康問題，特別是腎功能受損患者出現嚴重副作用風險增加，Gadoquatrane市場正經歷重大變革。這推動了對替代品的需求，尤其是無钆造影劑，其中氧化鐵奈米顆粒和錳基溶液作為極具潛力的候選藥物脫穎而出。對病患安全的關注以及對創新診斷影像解決方案的追求，正推動對這些新型造影劑的投資和研發，迫使製造商優先開發更安全、更有效的診斷造影劑。這一趨勢凸顯了診斷成像領域變革時期，並強調了該行業致力於改善患者預後的決心。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Bayer AG（Germany）
GE Healthcare（United States）
Guerbet Group（France）
Bracco Imaging SpA（Italy）
Lantheus Medical Imaging, Inc.（United States）
Daiichi Sankyo Company, Limited（Japan）
Spago Nanomedical AB（Sweden）
Trivitron Healthcare（India）
Jodas Expoim Pvt. Ltd.（India）
CMR Naviscan Corporation（United States）
Subhra Pharma Pvt. Ltd.（India）
Macrocyclics, Inc.（United States）
iMax Diagnostic Imaging Limited（China）
Beijing Beilu Pharmaceutical Co., Ltd.（China）
Jiangsu Hengrui Medicine Co., Ltd.（China）
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.（China）
Yantai Dongcheng Pharmaceutical Group Co., Ltd.（China）
Sanochemia Pharmazeutika AG（Austria）
Medtronic plc（Ireland）

結論與建議

簡介目錄

Product Code: SQMIG35I2135

Gadoquatrane Market size was valued at USD 2.0 Billion in 2024 and is poised to grow from USD 2.1 Billion in 2025 to USD 3.13 Billion by 2033, growing at a CAGR of 5.1% during the forecast period (2026-2033).

Market insights suggest a substantial growth trajectory for MRI contrast media agents, particularly with the introduction of gadoquatrane, a novel, highly potent macrocyclic gadolinium-based contrast agent (mGBCA). Gadoquatrane offers exceptional physicochemical properties, including high relaxivity and stability, coupled with negligible protein binding, mirroring the pharmacokinetic profiles of existing mGBCAs characterized by rapid extracellular distribution and effective renal excretion. This growth in demand is primarily fueled by the rising incidence of chronic conditions such as cancer, neurological disorders, and cardiovascular diseases, all of which necessitate advanced imaging techniques for accurate diagnosis and treatment planning. Furthermore, an aging population and a growing preference for non-invasive diagnostic methods are anticipated to bolster the market for MRI contrast agents significantly.

Top-down and bottom-up approaches were used to estimate and validate the size of the Gadoquatrane market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Gadoquatrane Market Segments Analysis

Global Gadoquatrane Market is segmented by Application, End User and region. Based on Application, the market is segmented into Screening and Diagnosis. Based on End User, the market is segmented into Hospital, Diagnostic Centres, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Gadoquatrane Market

The Gadoquatrane market is being driven by a robust demand for MRI contrast media agents, fueled by factors such as the rising prevalence of chronic diseases, an aging population, and the growing preference for non-invasive diagnostic procedures. Additionally, advancements in technology and increased healthcare spending are contributing to this upward trend. Gadolinium-based contrast agents (GBCAs) have long been recognized for their effectiveness in contrast-enhanced magnetic resonance imaging (CE-MRI), with millions of procedures utilizing these agents globally. The superior imaging capabilities offered by CE-MRI span various medical fields, enhancing diagnosis and disease management, which positions Gadoquatrane as a promising candidate for future clinical applications.

Restraints in the Gadoquatrane Market

Several factors can limit the demand and contribute to the decrease in prices for MRI contrast media agents. High costs associated with these agents, along with emerging safety concerns, play a significant role in this dynamic. Additionally, the rise of alternative diagnostic methods and a shift towards value-based healthcare further amplify these constraints. Advances in non-contrast MRI techniques are enhancing precision and efficiency, thereby reducing the necessity for contrast agents. Patients and healthcare providers may prefer more cost-effective non-contrast options as healthcare expenses rise. Although generally considered safe, awareness of potential side effects may prompt some to avoid contrast agents altogether, impacting market demand.

Market Trends of the Gadoquatrane Market

The Gadoquatrane market is experiencing a notable shift driven by rising health concerns associated with gadolinium-based contrast agents, particularly their potential severe side effects in patients with compromised kidney function. This has catalyzed a growing demand for alternatives, specifically gadolinium-free contrast agents, with iron oxide nanoparticles and manganese-based solutions emerging as promising contenders. The focus on patient safety and the quest for innovative imaging solutions are steering investment and research towards these novel agents, compelling manufacturers to prioritize the development of safer, effective diagnostics. This trend highlights a transformative phase in the imaging landscape, emphasizing the industry's commitment to enhancing patient outcomes.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies

Global Gadoquatrane Market Size by Application & CAGR (2026-2033)

Market Overview
Screening
Diagnosis

Global Gadoquatrane Market Size by End User & CAGR (2026-2033)

Market Overview
Hospital
Diagnostic Centres
Specialty Clinics
Others

Global Gadoquatrane Market Size & CAGR (2026-2033)

North America (Application, End User)
- US
- Canada
Europe (Application, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Application, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Application, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Application, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guerbet Group (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bracco Imaging S.p.A. (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lantheus Medical Imaging, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Spago Nanomedical AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Trivitron Healthcare (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jodas Expoim Pvt. Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CMR Naviscan Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Subhra Pharma Pvt. Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Macrocyclics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
iMax Diagnostic Imaging Limited (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beijing Beilu Pharmaceutical Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jiangsu Hengrui Medicine Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Yantai Dongcheng Pharmaceutical Group Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanochemia Pharmazeutika AG (Austria)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments